Number of eligible patients: CDEC mentioned the uncertainty in the amount of individuals with moderately significant to intense hemophilia B in Canada eligible for etranacogene dezaparvovec. Clinical specialists consulted by CADTH indicated that some individuals who are classified as having moderate or average disorder could possibly have a significant bleeding https://hamidb457qon7.dailyhitblog.com/profile